Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein clearance and metabolism. PCSK9i are used in patients with familial hypercholesterolemia and for the secondary prevent...

Full description

Bibliographic Details
Main Authors: Rosaria Vincenza Giglio BD, PhD, Emir M. Muzurović MD, PhD, Angelo Maria Patti MD, PhD, Peter P. Toth MD, PhD, Manyoo A. Agarwal MD, Wael Almahmeed MD, Aleksandra Klisic MD, PhD, Marcello Ciaccio MD, PhD, Manfredi Rizzo MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2023-07-01
Series:Journal of Cardiovascular Pharmacology and Therapeutics
Online Access:https://doi.org/10.1177/10742484231186855

Internet

https://doi.org/10.1177/10742484231186855

Similar Items